Drug intelligence / Profile preview

PBF-1650

Development stage: Phase 1
Lead developer: Palobiofarma
Modality: Small Molecules
Administration: Oral

Overview

PBF-1650 is a selective, orally bioavailable small molecule antagonist of the adenosine A1 and A3 receptors. It is being developed primarily for the treatment of atopic dermatitis and psoriasis, with additional investigation in non-alcoholic steatohepatitis (NASH) and previously in idiopathic thrombocytopenic purpura. The drug acts by blocking adenosine A1 and A3 receptors, which are implicated in inflammatory pathways relevant to autoimmune and skin disorders. The developer is Palobiofarma, a Spanish biotechnology company specializing in drugs targeting adenosine receptors[1][2][3][4].

Targets

ADORA3 (Adenosine A3 receptor)

Beyond the preview

Go deeper on PBF-1650.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PBF-1650.

Explore the full profile